Related by context. All words. (Click for frequent words.) 75 atypical hyperplasia 69 advanced adenoma 68 lobular carcinoma 68 BRCA mutation carriers 67 pCR 67 breast carcinoma 67 lobular breast cancer 67 atypical ductal hyperplasia 66 advanced adenomas 66 endometrial carcinoma 66 BRCA2 mutation carriers 66 situ LCIS 66 SLNB 65 BRCA mutation 65 BRCA mutations 65 adenoma 65 PCa 65 invasive carcinoma 65 endometrial cancers 65 ductal cancer 65 HGPIN 65 BRCA1 mutations 65 micrometastases 65 lymph node metastasis 65 distant metastases 64 ductal carcinomas 64 MGUS 64 lobular cancer 64 thyroid nodules 64 thyroglobulin 64 contralateral breast cancer 64 CIN2 + 64 carcinoid tumor 64 leiomyomas 64 colorectal adenomas 64 adenomatous polyps 64 BRCA2 mutation 64 lymph node metastases 64 colorectal neoplasia 64 endometrial hyperplasia 64 abnormal mammogram 63 chlamydial infection 63 cervical carcinoma 63 epithelial ovarian cancer 63 prostate cancer CaP 63 node metastases 63 sentinel lymph node biopsy 63 oophorectomy 63 precursor lesions 63 mammographic density 63 invasive breast cancer 63 estrogen receptor negative 63 axillary lymph nodes 63 CIN3 63 BRCA1 mutation carriers 63 premalignant lesions 63 BRCA2 mutations 63 gastric adenocarcinoma 63 adenocarcinomas 63 urine cytology 62 estrogen receptor ER 62 recurrent VTE 62 breast carcinomas 62 ductal breast cancer 62 serous ovarian cancer 62 estrogen receptor positive 62 ductal carcinoma 62 progesterone receptor negative 62 neoplasia 62 histologically 62 catheter angiography 62 histological subtype 62 hamartomas 62 ADPKD 62 tumor recurrence 62 colorectal adenoma 62 elevated CRP 62 distant metastasis 62 micrometastasis 62 hip BMD 62 axillary dissection 62 hormone receptor negative 62 HER2 expression 62 cytologic 62 nodal metastases 62 colorectal carcinoma 61 breast lesions 61 lymph node involvement 61 biochemical recurrence 61 epithelial tumors 61 subclinical atherosclerosis 61 subclinical hyperthyroidism 61 EUS FNA 61 benign breast 61 coronary calcification 61 bilateral oophorectomy 61 invasive ductal 61 subclinical 61 subclinical hypothyroidism 61 epithelial ovarian 61 PSADT 61 advanced neoplasia 61 colorectal polyps 61 IgA deficiency 61 operable breast cancer 61 mucinous 61 seminomas 61 pelvic ultrasound 61 troponin T 61 Heavy menstrual bleeding 61 urothelial carcinoma 61 thyroidectomy 61 nonmelanoma skin cancers 61 colorectal polyp 61 metachronous 61 microscopic hematuria 61 adenomas 61 #F FDG PET 61 benign polyps 61 BRCA gene mutation 61 MetS 61 CMV infection 61 mammographically 61 pancreatic adenocarcinoma 61 sentinel nodes 60 uterine cancers 60 renal cell carcinomas 60 HNSCC 60 situ DCIS 60 endometrial 60 FGFR2 gene 60 carotid stenosis 60 lymphocytosis 60 hormone receptor positive 60 precancerous polyp 60 DCIS 60 NMP# 60 vertebral fracture 60 histologic subtype 60 hereditary breast cancer 60 neoplasm 60 invasive lobular carcinoma 60 specific antigen PSA 60 BRCA2 carriers 60 antigen PSA 60 ovarian carcinoma 60 recurrent miscarriage 60 immunohistochemical staining 60 ductal 60 esophageal squamous cell carcinoma 60 ALCL 60 malignant lesions 60 extracapsular extension 60 mammographic breast density 60 biochemical relapse 60 deCODE BreastCancer TM 60 prostate biopsy 60 CaP 60 supratentorial 60 SUVmax 60 thyroid carcinoma 60 contralateral breast 60 HER2 amplification 60 immunohistochemical 60 irregular menstrual cycles 60 parathyroid 60 postmenopausal hormones 60 polycystic ovary syndrome PCOS 60 B7 H3 60 GISTs 60 lobular carcinomas 60 BRCA1 60 malignancy 60 hydronephrosis 60 adnexal mass 60 testicular germ cell 60 locoregional recurrence 60 chromosomal abnormalities 60 perineural invasion 60 Recurrence Score 59 APOE e4 59 HER2 negative 59 breast cancer recurrence 59 fine needle aspiration 59 papillary thyroid carcinoma 59 HER2 overexpression 59 clinically detectable 59 proximal colon 59 nonmelanoma skin cancer 59 distal colon cancer 59 pheochromocytomas 59 metastatic lesions 59 BRCA1 mutation 59 nonproliferative 59 chromosomal aberrations 59 coronary artery calcium 59 coronary stenosis 59 poorer prognosis 59 thyrotropin levels 59 cancerous breast 59 multivariable analysis 59 scintigraphic 59 recurrent UTI 59 lobular 59 papillary 59 core needle biopsy 59 hepatocellular carcinomas 59 #.#ng/ml 59 FDG uptake 59 cTnT 59 thiopurine 59 microbleeds 59 penetrance 59 neurofibromas 59 precancerous cervical 59 pre eclamptic 59 pulmonary metastases 59 colorectal neoplasms 59 tumor histology 59 autoantibodies 59 serum prostate 59 hematuria 59 hypercalcemia 59 serum estradiol 59 nodal metastasis 59 PARP inhibition 59 ASCUS 59 prognostic marker 59 BRCA deficient 59 surgical biopsy 59 cerebral microbleeds 59 LV dysfunction 59 prognostic significance 59 thyroid nodule 59 GSTT1 59 adrenalectomy 58 specific antigen 58 hamartoma 58 urolithiasis 58 microcalcifications 58 precancerous condition 58 benign proliferative breast 58 gastric carcinoma 58 chorioamnionitis 58 Endometrial 58 microsatellite instability 58 untreated celiac disease 58 CVD mortality 58 p# mutations 58 benign lesions 58 systolic dysfunction 58 perioperative complications 58 cerebral infarction 58 GSTP1 58 pre cancerous lesion 58 lymph node removal 58 angiographically 58 Hashimoto thyroiditis 58 incidentalomas 58 HNPCC 58 HER2 amplified 58 venous thromboembolism 58 basal cell nevus syndrome 58 ductal adenocarcinoma 58 Hurthle cell 58 carotid IMT 58 premenopausal breast cancer 58 histopathologic 58 nonalcoholic steatohepatitis NASH 58 NMIBC 58 pelvic lymphadenectomy 58 PSA velocity 58 premenopausal 58 breast cancers 58 sentinel node biopsy 58 ERalpha 58 sonographic findings 58 cervical intraepithelial neoplasia 58 serum PSA 58 adjuvant radiotherapy 58 Endometrial cancer 58 radical nephrectomy 58 tracer uptake 58 sentinel node 58 axillary node 58 cTnI 58 thyrotropin 58 PCNSL 58 malignant polyps 58 Clusterin 58 total thyroidectomy 58 adrenal masses 58 cytoreductive surgery 58 definite stent thrombosis 58 excisional biopsy 58 Lymph node 58 esophageal adenocarcinoma 58 polyp recurrence 58 CIN3 + 58 orchiectomy 58 TT genotype 58 prostate specific 58 TMPRSS2 ERG fusion 58 Lp PLA 2 58 invasive carcinomas 58 distal colon 58 amenorrhoea 58 HbF 58 colorectal liver metastases 58 androgen deficiency 58 folate intake 58 clinically insignificant 58 carotid artery thickness 58 p# mutation 58 PSA nadir 58 neoplasms 58 serum testosterone levels 58 genes BRCA1 58 lung nodules 58 tumoral 58 EBRT 58 Adjuvant chemotherapy 58 liver metastasis 58 fibroadenomas 58 rebleeding 58 coronary calcium 58 rs# [002] 58 venous thrombosis 58 basal cell carcinoma BCC 58 breast tumors 58 brain lesions 58 squamous cell lung cancer 58 sarcomatoid 58 papillary thyroid cancer 58 fibrocystic 58 lobular involution 58 ductal lobular 58 mesotheliomas 58 familial AF 58 KRAS mutations 58 intestinal polyps 58 microvascular disease 58 salpingo oophorectomy 58 scintigraphy 58 grade cervical intraepithelial 58 carotid plaque 58 intima media thickness 58 albumin excretion 58 TIMP 58 risk reducing salpingo 58 p#INK#a 58 antiphospholipid antibodies 58 LQTS 58 Ki# 58 carcinoma 57 neoplasia PIN 57 breast biopsies 57 bone metastasis 57 arteriography 57 pre malignant lesions 57 K ras mutations 57 BRAF mutation 57 BRAF mutations 57 ischemic lesions 57 TP# mutations 57 contralateral prophylactic mastectomy 57 VUR 57 squamous cell carcinoma SCC 57 cystatin C 57 colorectal tumors 57 HER2 receptor 57 prostate carcinoma 57 paragangliomas 57 phytoestrogen intake 57 gallstone disease 57 lung metastasis 57 hyperplasia 57 cytokeratin 57 progesterone receptor PR 57 colorectal cancer CRC 57 mIU L 57 BRCA2 57 malignant prostate 57 D dimer 57 osteoblastic 57 prophylactic mastectomy 57 cutaneous melanoma 57 varicoceles 57 peritoneal cancer 57 grade squamous intraepithelial 57 cervical lesions 57 prophylactic mastectomies 57 postmenopausal estrogen 57 POAG 57 PITX2 57 endometrial biopsy 57 familial ALS 57 hyperplastic 57 thrombophilia 57 thromboembolic disease 57 inherited mutations 57 white matter hyperintensities 57 premalignant 57 univariate analysis 57 recurrent ovarian 57 colon polyps 57 seminal vesicle invasion 57 dysplasia 57 postmenopausal breast cancer 57 MALT lymphoma 57 N telopeptide 57 TMPRSS2 ERG 57 spontaneous preterm birth 57 STRIDE PD 57 spontaneous preterm delivery 57 estrogen receptor progesterone receptor 57 postoperative morbidity 57 rheumatoid factor 57 Papillary 57 metastases 57 osteosarcomas 57 pre cancerous polyps 57 adenomatous 57 thyroid dysfunction 57 clinicopathological features 57 digital rectal examination 57 perioperative mortality 57 neoadjuvant therapy 57 obstructive coronary artery 57 prostate adenocarcinoma 57 dysglycemia 57 HER2 positive tumors 57 LCIS 57 endometriosis ovarian cysts 57 abnormal mammograms 57 postoperative pulmonary 57 SHBG levels 57 neurodevelopmental outcome 57 neoadjuvant chemotherapy 57 abnormal cytology 57 postoperative mortality 57 BRCA2 gene 57 response pCR 57 thickness CIMT 57 MGd 57 medullary thyroid cancer 57 precancerous tumors 57 electron beam computed tomography 57 parous women 57 immunohistochemical analysis 57 postmenopausal hormone 57 HER2 positive cancers 57 microalbuminuria 57 carcinoembryonic antigen 57 invasive ductal carcinoma 57 varicocele 57 F FDG PET 57 screening mammogram 57 lymphoproliferative disorders 57 CC genotype 57 chromosomal alterations 57 neoplasias 57 lymphovascular invasion 57 fibrocystic changes 57 clinicopathological 57 metaplasia 57 extracolonic findings 57 lymphadenectomy 57 elevated depressive symptoms 57 atypical lobular hyperplasia 57 bladder tumors 57 pancreatic endocrine 57 carcinomas 57 pT2 57 prostate cancer PCa 57 adenoma recurrence 57 thyrotoxicosis 57 lactate dehydrogenase LDH 57 transabdominal 57 pretest probability 57 hormone receptor status 57 basal cell carcinomas 57 bone scintigraphy 57 atherothrombotic disease 57 ICD implantation 57 somatic mutations 57 uveal melanoma 57 diabetes mellitus DM 57 fetal malformations 57 Cholangiocarcinoma 57 histopathologic diagnosis 57 adenocarcinoma 57 malignancies 57 TGFBR1 * 6A 57 estrogen progestin therapy 57 HER2 ErbB2 57 pathologic fractures 57 FGFR2 57 SPINK1 57 bowel polyps 57 GBA mutations 57 HBV infection 57 R0 resection 57 chromosomal rearrangement 57 Prostate specific antigen 57 microdeletions 57 esophageal cancers 57 sentinel lymph nodes 57 meningioma 57 metastatic disease 57 Tumor shrinkage 57 lung metastases 57 PALB2 57 extracranial 57 cytological 57 thromboembolism 57 undergone hysterectomy 57 serum phosphate 57 hormone therapy estrogen 57 AGTR1 57 anti JCV antibodies 57 perimenopausal women 57 β blockers 56 EpCAM expression 56 nonfasting triglyceride levels 56 Her2 56 diagnostic biomarker 56 abnormal Pap test 56 endometrioid 56 axillary lymph node dissection 56 bacteriuria 56 endometrial cancer 56 clinically localized prostate 56 adrenal function 56 testicular tumors 56 axillary nodes 56 mutated BRCA1 56 mutated K ras 56 submucosal 56 nephrogenic 56 Uterine fibroids 56 ductal lavage 56 colorectum 56 perfusion defects 56 undetectable PSA 56 maternal serum 56 transurethral resection 56 polyposis 56 preoperative PSA 56 endometrial thickness 56 uterine tumors 56 oesophageal adenocarcinoma 56 germline mutations 56 IDH1 mutation 56 ovarian cancers 56 cystectomy 56 histologic examination 56 monoclonal gammopathy 56 dysplastic nevi 56 colorectal adenocarcinoma 56 cardiac troponin 56 transaminase levels 56 aminotransferases 56 mammary tumors 56 homozygotes 56 arterial calcification 56 osteoid 56 upper endoscopy 56 KRAS mutation 56 prognostic biomarker 56 aneuploidy 56 protein excretion 56 multivariable adjusted 56 proteinuria 56 hepatoma 56 radioiodine therapy 56 liver metastases 56 PTPN# 56 renal tumors 56 acute aortic dissection 56 familial aggregation 56 gynecologic malignancy 56 amenorrhea 56 histopathologic examination 56 intestinal metaplasia 56 helical CT 56 curative resection 56 mRNA expression 56 papillary carcinoma 56 precancerous cervical lesions 56 KCNE2 56 breast endometrial 56 macroalbuminuria 56 colon tumors 56 invasive ductal breast cancer 56 TIMP 1 56 atrophic gastritis 56 albuminuria 56 dose ionizing radiation 56 hepatic steatosis 56 serum calcium levels 56 Uterine cancer 56 gene polymorphism 56 differentiated thyroid 56 chromosomal instability 56 hypopituitarism 56 thymoma 56 promoter methylation 56 Chronic pancreatitis 56 bronchopulmonary dysplasia 56 malignant neoplasm 56 Multivariate analysis 56 underwent resection 56 fetal chromosomal 56 fasting insulin 56 HCV antibody 56 thyroid cancers 56 adjuvant radiation 56 ERBB2 56 bladder cancers 56 cystoscopic 56 ovarian tumors 56 BRCA2 gene mutations 56 malignant transformation 56 hereditary hemochromatosis 56 BRCA2 gene mutation 56 univariate analyzes 56 endoscopic ultrasonography 56 transferrin saturation 56 immunoreactivity 56 pericardial effusion 56 SGPT 56 benign noncancerous 56 pleomorphic 56 pathologic diagnosis 56 BRAF V#E 56 molar pregnancy 56 ovarian malignancy 56 hypermethylation 56 benign growths 56 stratifying patients 56 androgen suppression 56 hyperplastic polyps 56 thromboembolic 56 gadolinium enhanced 56 malignant nodules 56 gastric cardia 56 Prostatitis 56 testicular cancers 56 glomerular filtration 56 MR spectroscopy 56 gestational diabetes mellitus 56 deCODE BreastCancer 56 mesangial 56 cellularity 56 EBUS FNA 56 follicular thyroid cancer 56 androgen ablation 56 multivariate logistic regression 56 KRAS oncogene 56 Squamous 56 RASSF1A 56 breast asymmetry 56 intraepithelial neoplasia 56 grade dysplasia 56 ovulation induction 56 postoperative radiotherapy 56 renal carcinoma 56 Subgroup analyzes 56 endometrial lining 56 thromboembolic events 56 pulmonary angiography 56 biopsy 56 TOP2A 56 esophageal carcinoma 56 oropharyngeal cancer 56 colorectal tumor 56 leiomyoma 56 adrenocortical 56 intact parathyroid hormone 56 chemoembolization 56 paroxysmal AF 56 vestibular schwannomas 56 biopsies 56 CD#c 56 deep venous thrombosis 56 thyroid hormone levels 56 Stent thrombosis 56 densest breasts 56 radical prostatectomy RP 56 Adjuvant therapy 56 TRAF1 C5 56 GIST tumors 56 calculi 56 mammary cancers 56 ovarian cancer 56 microvessel density 56 premature menopause 56 rs# [004] 56 fibroadenoma 56 neoplastic 56 telomere lengths 56 myocardial ischemia 56 choriocarcinoma 56 serum thyroglobulin 56 lactate dehydrogenase 56 CDH1 56 serum PTH 56 TCF#L# 56 GBM tumors 56 mesothelin 56 core needle biopsies 56 colonoscopic 56 hsCRP 56 axillary node dissection 55 metastatic lymph nodes 55 ERCC1 55 sCJD 55 abnormalities 55 TNF blocker therapy 55 premature ovarian 55 #q# deletion 55 hepatectomy 55 metastatic malignant 55 nodular melanoma 55 Prostate Specific Antigen PSA 55 tHcy 55 hydrops 55 EBCT 55 creatinine ratio 55 Inhibin B 55 preterm delivery 55 EGFR protein 55 androgen deprivation 55 invasive cervical cancer 55 transitional cell carcinoma 55 mL/min/#.# m 2 55 aneuploidy screening 55 abnormal cervical 55 esophagogastric junction 55 gene amplification 55 Amniocentesis 55 arterial thickening 55 DXA scan 55 neurologic complications 55 familial pancreatic cancer 55 relapsed ovarian cancer 55 Ductal carcinoma 55 LVNC 55 lymph node biopsies 55 confidence interval #.#-#.# 55 NGAL 55 undergoing hysterectomy 55 atherosclerotic lesions 55 HER2 gene 55 anovulatory infertility 55 oral clefts 55 giant cell arteritis 55 cytologic examination 55 MSH2 55 highest tertile 55 postoperative complication 55 troponins 55 underarm lymph nodes 55 pathologic 55 neoadjuvant radiation 55 premenopausal women 55 HER2 positivity 55 invasive lobular 55 tumor subtypes 55 PSA kinetics 55 estrogen receptor alpha 55 morphological abnormalities 55 TMEM density 55 lymphadenopathy 55 radiochemotherapy 55 pleural mesothelioma 55 tPSA 55 HER2 positive metastatic breast 55 seroma 55 cancerous enlargement 55 colonic polyps 55 Adenomas 55 benign nodules 55 ALND 55 serum creatinine levels 55 sonographically 55 teratoma 55 breast tissue 55 noncardiac 55 appendiceal 55 rs# [001] 55 nephrolithiasis 55 naturally occurring estrogen 55 biochemical markers 55 myometrium 55 primary ovarian insufficiency 55 cTnT levels 55 nonmelanoma 55 chemopreventive agent 55 echogenicity 55 CHEK2 55 neoadjuvant 55 pre menopausal 55 rCBF 55 NAFLD 55 PGDH 55 Myocardial infarction 55 artery embolization 55 peritoneal carcinomatosis 55 pre cancerous lesions 55 chemoresistant 55 Ovary removal 55 HAAH 55 de ath 55 LHRH agonists 55 cervical lymph nodes 55 PTEN gene 55 glioblastoma tumors 55 nonmetastatic 55 lymph node dissection 55 intraoperative complications 55 gestational hypertension 55 hypermethylated 55 prolonged QT interval 55 cervical cytology 55 prognostic indicator 55 parathyroid carcinoma 55 nonhereditary 55 SLN biopsy 55 neoplastic lesions 55 hematological parameters 55 #p# [001] 55 Venous thromboembolism 55 hepatic metastases 55 noncancerous 55 metabolite concentrations 55 HBsAg 55 vasomotor symptoms 55 HER2 neu 55 ABCB1 55 leukoencephalopathy 55 breast cancer metastasis 55 tumor xenografts 55 lowest tertile 55 calcifications 55 ovulatory cycles 55 preventive mastectomy 55 postoperative complications 55 E selectin 55 APOE ε4 55 mediastinal 55 vascular endothelial 55 histologically confirmed 55 ultrasonographic 55 clinico pathological 55 coronary arteriography 55 breast cancer subtypes 55 Malignant tumors 55 genetic polymorphisms 55 venous blood clots 55 renal cysts 55 fibroids endometriosis 55 neuroblastoma tumors 55 pathologic examination 55 oncologic outcomes 55 MSMB 55 cardiac troponin T 55 pelvic lymph nodes 55 nulliparous 55 leukaemias 55 hypoperfusion 55 LHRH receptor positive 55 proliferative retinopathy 55 thyroid stimulating hormone 55 hematopoietic cancers 55 HER-2/neu 55 GNAQ 55 postoperative chemotherapy 55 skeletal metastases 55 dysplastic 55 Cytogenetic 55 VEGF expression 55 complete cytogenetic response 55 beta1 integrin 55 serum concentrations 55 postoperative AF 55 brain metastases 55 Kaplan Meier analysis 55 gene polymorphisms 55 malignant ovarian 55 proliferative diabetic retinopathy 55 carcinoid 55 BRAF V#E mutation 55 metastatic prostate 55 leukemia AML 55 arthrography 55 androgen suppression therapy 55 invasive coronary angiography 55 LRP5 55 cardiovascular mortality 55 parkinsonism 55 recurrent NSCLC 55 adjuvant chemotherapy 55 TGF ß1 55 atypical femur fractures 55 asymptomatic 55 sporadic ALS 55 proto oncogene 55 familial clustering 55 neoplastic cells 55 tumors 55 malignant growths 55 hypercalciuria 55 chemosensitivity 55 systemic lupus erythematosus SLE 55 tibolone 55 LV hypertrophy 55 vulvar cancer 55 hepatocellular carcinoma 55 pT3 55 urothelial cancer 55 LSIL 55 GnRH agonists 55 IUGR 55 nonfasting triglycerides 55 ectopic 55 atherogenic dyslipidemia 55 NP CRNs 55 meningiomas 55 screening colonoscopy 55 preoperative chemotherapy 55 serum homocysteine 55 postmenopausal hormone replacement 55 pituitary adenomas 55 axillary lymph node 55 baseline mammogram 55 normal karyotype 55 Immunohistochemical analysis 55 debulking surgery 54 spiral computed tomography 54 immunostaining 54 prognostic factor 54 FDG PET imaging 54 abnormal Pap smear 54 cyclin E 54 menstrual bleeding 54 Adenocarcinoma 54 prostate abnormalities 54 Coronary artery calcium 54 serum testosterone 54 kidney cysts 54 microglial 54 seropositivity 54 serum TSH 54 infarcts 54 cancerous polyps 54 locoregional 54 cancerous lesions 54 serum ferritin 54 squamous cell cancers 54 elevated homocysteine 54 papillary renal cell carcinoma 54 pheochromocytoma 54 abdominal adiposity 54 creatinine levels 54 estrogen receptor 54 EGFR mutation 54 nonischemic 54 congenital malformations 54 perfusion imaging 54 preventive mastectomies 54 KRAS wild 54 polyp detection 54 alanine aminotransferase ALT 54 spontaneous regression 54 multivariate adjustment 54 estrogen progesterone 54 chronic prostatitis 54 thromboembolisms 54 SHBG 54 nonvertebral fractures 54 platelet reactivity 54 abnormal uterine bleeding 54 histopathologic findings 54 histologic subtypes 54 undergoing radical prostatectomy 54 abdominal hysterectomy 54 endometrial tissue 54 low expressors 54 sentinel lymph node 54 HBeAg seroconversion 54 vesicoureteral reflux 54 Brugada syndrome 54 μg dL 54 HBeAg 54 transfusion syndrome 54 benign prostatic hypertrophy 54 bone resorption